July 24, 2021
Author Derrick Broze

The Great Reset agenda is aimed at instituting a world technocratic control with a transhumanist bent. Is Ginko Bioworks one of the companies who will help create this nightmare?

In May, biotech firm Ginkgo Bioworks announced it was going public with a valuation of $15 billion. Ginkgo is a rising star in the biotechnology field, describing themselves as “The Organism Company”. While their name is less known than other biotech giants such as Monsanto and Bayer, the scope of their research and projects will likely affect billions of people around the world in coming years.

Ginkgo Bioworks was founded in 2009 by a group of MIT scientists focused on “engineering biology” for a variety of purposes. Officially, Ginkgo Bioworks “designs, engineers, develops, tests and licenses organisms”. The company refers to their work as “biology by design”, stating that they “program cells to make everything from food to materials to therapeutics.” Ginkgo’s researchers use genetic engineering to design and “print” new DNA for a range of organisms, including plants and bacteria. These organisms can then be licensed out for artificial flavors and sweeteners, cosmetic ingredients, crop treatments and pharmaceuticals.

What Ginkgo lacks in name recognition they make up for in financial investments. In March 2015, Ginkgo raised $9 million from investors during the company’s first significant fundraising round. A few months later they would receive another $45 million from a group led by Viking Global Investors. Just 3 years ago, the company was reportedly valued at over $1 billion after raising over $429 million in funding from investors, including Cascade Investment.

In November 2020 the U.S. government granted Ginkgo a $1.1 billion loan for “COVID-19 testing and the production of raw materials for therapies that may help address future pandemics”.

SNIP